Home/Pipeline/XmAb®14045

XmAb®14045

Acute Myeloid Leukemia (AML)

Phase 2Active (Partnered)

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 2

Status

Active (Partnered)

Company

Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active